Literature DB >> 30690635

A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.

Ruth J Pepper1, Stephen P McAdoo2,3, Sarah M Moran4, Dearbhla Kelly4, Jennifer Scott4, Sally Hamour1, Aine Burns1, Megan Griffith2,3, Jack Galliford3, Jeremy B Levy2,3, Thomas D Cairns3, Seerapani Gopaluni5, Rachel B Jones5, David Jayne5, Mark A Little4,6, Charles D Pusey2,3, Alan D Salama1.   

Abstract

Entities:  

Year:  2019        PMID: 30690635     DOI: 10.1093/rheumatology/kez001

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  4 in total

1.  Glucocorticoid-free treatment of severe ANCA-associated vasculitis.

Authors:  Tariq E Farrah; Maria Prendecki; Robert W Hunter; Rashmi Lahiri; Thomas D Cairns; Charles D Pusey; Stephen P McAdoo; Neeraj Dhaun
Journal:  Nephrol Dial Transplant       Date:  2021-03-29       Impact factor: 5.992

Review 2.  Anti-neutrophil Cytoplasmic Antibodies (ANCA) as Disease Activity Biomarkers in a "Personalized Medicine Approach" in ANCA-Associated Vasculitis.

Authors:  Mohammed S Osman; Jan Willem Cohen Tervaert
Journal:  Curr Rheumatol Rep       Date:  2019-12-26       Impact factor: 4.592

3.  Glucocorticoid maintenance therapy and severe infectious complications in ANCA-associated vasculitis: a retrospective analysis.

Authors:  Claudius Speer; Christine Altenmüller-Walther; Jan Splitthoff; Christian Nusshag; Florian Kälble; Paula Reichel; Christian Morath; Martin Zeier; Raoul Bergner; Matthias Schaier
Journal:  Rheumatol Int       Date:  2020-11-22       Impact factor: 2.631

4.  Utility of interval kidney biopsy in ANCA-associated vasculitis.

Authors:  Gavin B Chapman; Tariq E Farrah; Fiona A Chapman; Dan Pugh; Christopher O C Bellamy; Rashmi Lahiri; Eve Miller-Hodges; David C Kluth; Robert W Hunter; Neeraj Dhaun
Journal:  Rheumatology (Oxford)       Date:  2022-05-05       Impact factor: 7.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.